Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech (NASDAQ:MENS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Jyong Biotech Responds to Share Price and Volume Movement
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry
Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs